Diagnosis and treatment in inflammatory neuropathies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 3, 2009, Pages 249-258

  Lunn, M P T ^a   Willison, H J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ECULIZUMAB; ETANERCEPT; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERFERON ALPHA2B; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PREDNISOLONE; RITUXIMAB; SODIUM CHANNEL BLOCKING AGENT; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; ACUTE MOTOR AXONAL NEUROPATHY; ACUTE MOTOR SENSORY AXONAL NEUROPATHY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; CUSHINGOID SYNDROME; DEMYELINATING NEUROPATHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GUILLAIN BARRE SYNDROME; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LEWIS SUMNER SYNDROME; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOCLONAL IMMUNOGLOBULINEMIA; MORBIDITY; MORTALITY; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY WITH CONDUCTION BLOCK; NEUROPATHY; NONHUMAN; PARAPROTEINEMIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PHYSIOTHERAPY; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULITIC NEUROPATHY; VASCULITIS; WEGENER GRANULOMATOSIS; CONNECTIVE TISSUE DISEASE; MOTOR NEURON DISEASE; NEUROLOGIC EXAMINATION; REVIEW;

CONNECTIVE TISSUE DISEASES; DIAGNOSIS, DIFFERENTIAL; GUILLAIN-BARRE SYNDROME; HUMANS; MOTOR NEURON DISEASE; NEUROLOGIC EXAMINATION; PARAPROTEINEMIAS; POLYRADICULONEUROPATHY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PROGNOSIS; VASCULITIS;

EID: 61549087486     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.158303     Document Type: Article

References (146)

1. Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999;53:2113-21.
2. Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C. Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin. Neuropathol 2008;27:96-105.
3. Kuwabara S, Dispenzieri A, Arimura K, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev 2008;CD006828.
4. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquide cephalorachidien sans réaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull Soc Méd Hôp Paris 1916;40:1462-70.
5. Markoula S, Giannopoulos S, Sarmas I, et al. Guillain-Barré syndrome in northwest Greece. Acta Neurol Scand 2007;115:167-73.
6. Bogliun G, Beghi E. Validity of hospital discharge diagnoses for public health surveillance of the Guillain-Barré syndrome. Neurol Sci 2002;23:113-7.
7. Alshekhlee A, Hussain Z, Sultan B, et al. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 2008;70:1608-13.
8. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993:33:333-42.
9. Hagemans ML, Laforet P, Hop WJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord 2007.
10. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-8.
11. Visser LH, Schmitz PI, Meulstee J, et al. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 1999;53:598-604.
12. Murray NM, Wade DT. The sural sensory action potential in Guillain-Barré syndrome. Muscle Nerve 1980;3:444.
13. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17.
14. Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45:168-73.
15. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain- Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-16.
16. Meyer zu HG, Hartung HP, Kieseier BC. From bench to bedside-experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007;3:198-211.
17. Rees JH, Thompson RD, Smeeton NC, et al. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998;64:74-7.
18. Forsberg A, Press R, Einarsson U, et al. Disability and health-related quality of life in Guillain-Barré syndrome during the first two years after onset: a prospective study. Clin Rehabil 2005;19:900-9.
19. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain- Barré syndrome. Arch Neurol 2005;62:1194-8.
20. Hughes RA, Swan AV, van KR, et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006;CD001446.
21. Brettle RP, Gross M, Legg NJ, et al. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978;2:1100.
22. Creange A, Sharshar T, Raphael JC, et al. Cellular aspect of neuroinflammation in Guillain-Barré syndrome: a key to a new therapeutic option?. Rev Neurol (Paris) 2002;158:15-27.
23. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-61.
24. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41:298-306.
25. Kleyweg RP, van der Meche FG, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988;38:1639-41.
26. Hughes RA, Raphael JC, Swan AV, et al. Intravenous immunoglobulin for Guillain- Barré syndrome. Cochrane Database Syst Rev 2006;CD002063.
27. Bechtold DA, Yue X, Evans RM, et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 2005;128:18-28.
28. Halstead SK, Humphreys PD, Goodfellow JA, et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 2005;58:203-10.
29. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131:1197-208.
30. Hepburn NJ, Williams AS, Nunn MA, et al. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 2007;282:8292-9.
31. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7.
32. European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005;10:220-8.
33. Mahdi-Rogers M, Al-Chalabi A, Hughes RAC. Prevalence and morbidity of chronic inflammatory neuropathies in South East England. J Peripher Nerv Syst 2008;13(1 Suppl):176.
34. Koski CL, Baumgarten M, Magder LS, et al. Development of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2007;12(1 Suppl):46.
35. Tackenberg B, Lunemann JD, Steinbrecher A, et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007;68:1622-9.
36. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Medicine 1969;48:173-215.
37. Salomon B, Rhee L, Bour-Jordan H, et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 2001;194:677-84.
38. Yan WX, Taylor J, Andrias-Kauba S, et al. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000;47:765-75.
39. Winer J, Hughes S, Cooper J, et al. Gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002;249:616-21.
40. Kiefer R, Dangond F, Mueller M, et al. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J Neurol Neurosurg Psychiatry 2000;69:362-8.
41. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002;59:7-12S.
42. Kieseier BC, Clements JM, Pischel HB, et al. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 1998;43:427-34.
43. Kanda T, Numata Y, Mizusawa H. Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated Z0-1. J Neurol Neurosurg Psychiatry 2004;75:765-9.
44. Austin JH. Recurrent polyneuropathies and their corticosteroid treatment. Brain 1958;81:157-92.
45. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981;9(Suppl):134-45.
46. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110:1617-30.
47. Barohn RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyradiculopathy: Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-84.
48. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-41.
49. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Bev 2001;CD002062.
50. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-83.
51. Van Schaik IN, Winer JB, de Haan R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 2002;1:491-8.
52. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-44.
53. Lee DH, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008;37:406-9.
54. Levy RL, Newkirk R, Ochoa J. Treatment of chronic relapsing Guillain-Barré syndrome by plasma exchange. Lancet 1979;2:741.
55. Server AC, Lefkowith J, Braine H, et al. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979;6:258-61.
56. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-5.
57. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, crossover study. Brain 1996;119:1055-66.
58. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
59. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-45.
60. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;CD003280.
61. Mahdi-Rogers M. for the Randomised Methotrexate Chronic Inflammatory Demyelinating Polyradiculoneuropathy RMC Trial Group. A pilot randomised controlled trial of methotrexate for CIDP: lessons for future trials. J Peripher Nerv Syst 2008;13(1 Suppl):176S.
62. Simmons Z, Albers JW, Bromberg MB, et al. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118:359-68.
63. Dyck PJ, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985;35:1173-6.
64. Chin RL, Sherman WH, Sander HW, et al. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003;210:19-21.
65. Ahlmen J, Andersen O, Hallgren G, et al. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998;30:4194.
66. Oyama Y, Sufit R, Loh Y, et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology 2007;69:1802-3.
67. Mahdi-Rogers M, Hughes RAC, kazmi, M, et al. Autologous peripheral blood progenitor cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2007;12(1 Suppl):55S.
68. Hirst C, Raasch S, Llewelyn G, et al. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006;77:800-2.
69. Pestronk A, Cornblath DR, llyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-8.
70. O'Leary CP, Mann AC, Lough J, et al. Muscle hypertrophy in multifocal motor neuropathy is associated with continuous motor unit activity. Muscle Nerve 1997;20:479-85.
71. Van Schaik IN, Bouche P, Ilia I, Leger JM, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006;13:802-8.
72. Taylor BV, Wright RA, Harper CM, et al. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-8.
73. Bigliardi-Qi M, Miescher GC, Steck AJ. Recognition of human recombinant myelin associated glycoprotein by anti-carbohydrate antibodies of the L2/HNK-1 family. Biochem Biophys Res Commun 1995;217:171-8.
74. Van Schaik IN, Van den Berg LH, de HR, et al. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005;CD004429.
75. Leger JM, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short-and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 2008;79:93-6.
76. Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007;69:1680-7.
77. Delmont E, Azulay JP, Uzenot D, et al. Long-term follow-up of multifocal motor neuropathy with conduction block under intravenous immunoglobulin. Rev Neurol (Paris) 2007;163:82-8.
78. Vucic S, Black KR, Chong PS, et al. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63:1264-9.
79. Leger JM, Behin A. Multifocal motor neuropathy. Curr Opin Neurol 2005;18:567-73.
80. Van den Berg LH, Franssen H, van Doorn PA, et al. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies. J Neurol Neurosurg Psychiatry 1997;63:674-7.
81. Lehmann HC, Hoffmann FR, Fusshoeller, et al. The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 2008;271:34-9.
82. Carpo M, Pedotti R, LoIIi F, et al. Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci 1998;155:186-91.
83. Umapathi T, Hughes RA, Nobile-Orazio E, et al. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2005;CD003217.
84. Corse AM, Chaudhry V, Crawford TO, et al. Sensory nerve pathology in multifocal motor neuropathy. Ann Neurol 1996;39:319- 25.
85. Benedetti L, Grandis M, Nobbio L, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004;29:748-9.
86. Piepers S, Van dB-V, van der Pol WL, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain 2007;130:2004-10.
87. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-9.
88. Rojas-Garcia R, Gallardo E, de Al, et al. Chronic neuropathy with IgM arrti-ganglioside antibodies: lack of long term response to rituximab. Neurology 2003;61:1814-16.
89. Gorson KC, Natarajan N, Ropper AH, et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007;35:66-9.
90. Chaudhry V, Cornblath DR. An open-label trial of rituximab (rituxan) in multifocal motor neuropathy (MMN). J Peripher Nerv Syst 2008;13(1 Suppl):164S.
91. Nemni R, Santuccio G, Calabrese E, et al. Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol 2003;250:1118-20.
92. Martina IS, van Doom PA, Schmitz PI, et al. Chronic motor neuropathies: response to interferon-betala after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999;66:197-201.
93. Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Treatment of multifocal motor neuropathy with interferon-beta1A. Neurology 2000;54:1518-21.
94. Terenghi F, Cocito D, Casellato C, et al. Efficacy and tolerability of oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy treated with IVIg. J Peripher Nerv Syst 2008;13(1 Suppl):183S.
95. Bouche P, Moulonguet A, Younes-Chennoufi AB, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995:59:38-44.
96. Axelson HW, Oberg G, Askmark H. No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand 2008;117:432-4.
97. Kelly JJJ, Kyle RA, O'Brien PC, et al. The prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31:1480-3.
98. Silverstein A, Doniger DE. Neurologic complications of myelomatosis. Arch Neurol 1963;9:534-44.
99. Kahn SN, Riches PG, Kohn J. Paraproteinaemia in neurological disease: incidence, associations and classification of monoclonal immunoglobulins. J Clin Pathol 1980;33:617-21.
100. Vrethem M, Cruz M, Wen-Xin H, et al. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 1993;114:193-9.
101. Osby E, Noring L, Hast R, et al. Benign monoclonal gammopathy and peripheral neuropathy. Br J Haematol 1982;51:531-9.
102. Ilyas AA, Gu Y, Dalakas MC, et al. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol 2008;193:87-93.
103. Allen D, Lunn M, Niermeijer J, et al. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev 2007;CD005376.
104. Eurelings M, Lokhorst HM, Notermans NC, et al. Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy. J Neurol Sci 2007;260:124-31.
105. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucoronyl paraglobiside. Brain 1994;117:941-7.
106. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615-20.
107. Willison HJ, O'Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;124:1968-77.
108. Simmons Z, Bromberg MB, Feldman EL, et al. Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve 1993;16:77-83.
109. Keren DF, Warren JS, Lowe JB. Strategy to diagnose monoclonal gammopathies in serum: high resolution electrophoresis, immunofixation, and kappa/lambda quantification. Clin Chem 1988;34:2196-201.
110. Ponsford S, Willison H, Veitch J, et al. Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy [see comments]. Muscle and Nerve 2000;23:164-74.
111. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006;CD002827.
112. Notermans NC, Lokhorst HM, Franssen H, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996;47:1227-33.
113. Niermeijer JM, Eurelings M, van der Linden MW, et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology 2007;69:50-9.
114. Wilson HC, Lunn MP, Schey S, et al. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999;66:575-80.
115. Niermeijer JM, Eurelings M, Lokhorst H, et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology 2006;67:2076-9.
116. Mariette X, Léger JM, Chevret S, et al. A randomized double-blind trial versus placebo do not confirm the efficacy of alpha-interferon in polyneuropathy associated with anti-MAG IgM monoclonal gammopathy. J Neurol Neurosurg Psychiatry 2000;69:279-80.
117. Nobile-Orazio E, Casellato C, Di TA. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris) 2002;158:979-87.
118. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. New Engl J Med 1991;325:1482-6.
119. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
120. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990;33:1065-7.
121. Bruce ME, Will RG, Ironside JG, et al. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 1997;389:498-501.
122. Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain 1987;110(Pt 4):843-53.
123. Collins MP, Periquet Ml, Mendell JR, et al. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology 2003;61:623-30.
124. Sehgal M, Swanson JW, DeRemee RA, et al. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc 1995;70:337-41.
125. Guillevin L, Le Thi HD, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988;27:258-64.
126. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
127. Lane SE, Watts RA, Shepstone L, et al. Primary systemic vasculitis: clinical features and mortality. QJM 2005;98:97-111.
128. Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol 2005;252:633-41.
129. Zaltron S, Puoti M, Liberini P, et al. High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia. Ital J Gastroenterol Hepatol 1998;30:391-5.
130. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999;42:2507-16.
131. Mahadevan A, Gayathri N, Taly AB, et al. Vasculitic neuropathy in HIV infection: a clinicopathological study. Neurol India 2001;49:277-83.
132. Mathew L, Talbot K, Love S, et al. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM 2007;100:41-51.
133. Chen CS, Lee AW. Management of acute central retinal artery occlusion. Nat Clin Pract Neurol 2008;4:376-83.
134. Breynaert C, Cornells T, Stroobants S, et al. Systemic lupus erythematosus complicated with aortitis. Lupus 2008;17:72-4.
135. Blockmans D, Stroobants S, Maes A, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000;108:246-9.
136. Carels T, Verbeken E, Blockmans D. p-ANCA-associated periaortitis with histological proof of Wegener's granulomatosis: case report. Clin Rheumatol 2005;24:83-6.
137. Said G, Lacroix-Ciaudo C, Fujimura H, et al. The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol 1988;23:461-5.
138. Collins MP, Mendell JR, Periquet Ml, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000;55:636-43.
139. Burns TM, Schaublin GA, Dyck PJ. Vasculitic neuropathies. Neurol Clin 2007;25:89-113.
140. Vrancken AF, Hughes RA, Said G, et al. Immunosuppressive treatment for nonsystemic vasculitic neuropathy. Cochrane Database Syst Rev 2007;CD006050.
141. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003:349:36-44.
142. Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995;74:238-53.
143. Scelsa SN, Herskovitz S, Reichler B. Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia. Muscle Nerve 1998;21:1526-9.
144. Cacoub P, Lidove 0, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317-26.
145. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
146. Sansonno D, De RV, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26.